NCT03661632View on ClinicalTrials.gov

An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

September 11, 2018

Primary Completion Date

November 11, 2019

Study Completion Date

December 29, 2020

Conditions
Advanced Cancer
Interventions
DRUG

BMS-986310

Specified dose on specified days

BIOLOGICAL

Nivolumab

Specified dose on specified days

Trial Locations (7)

1200

Local Institution, Brussels

9000

Local Institution, Ghent

15213

UPMC Hillman Cancer Center, Pittsburgh

63110

Washington University School of Medicine, St Louis

77030

MD Anderson Cancer Center, Houston

07601

Hackensack University Medical Center, Hackensack

M5G 1Z5

Local Institution, Toronto

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY